Near-Term Bullish Options Activity in AbbVie (ABBV) Targets Upside Above $90 Amid Rally in Shares -Susuqehanna

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 9/18/2026

1. SPY
2. XENE
3. NUE
4. HUBS
5. RTB
6. ONON
7. AAPL
8. ACN
9. AZN
10. SPCX

Go back to Near-Term Bullish Options Activity in AbbVie (ABBV) Targets Upside Above $90 Amid Rally in Shares -Susuqehanna

Speculative Bullish Options Flow in AbbVie (ABBV) as Management Presents at Healthcare Conference -Susquehanna

September 12, 2017 2:33 PM EDT

Susquehanna options strategist Alison Edwards notes speculative bullish options flow in AbbVie (NYSE: ABBV), with management presenting at a healthcare conference, as an investor sold 2k Nov 85/92.5 call spreads at $4.78 (getting long the 92.5 strike options), possibly a buyer of 2,500 Jan 95 Calls for $1.50, while... More

AbbVie (ABBV) Reports Upadacitinib (ABT-494) Meets All Primary & Ranked Secondary Endpoints in Second Phase 3 Study

September 11, 2017 8:03 AM EDT

AbbVie (NYSE: ABBV) today announced positive top-line results from the Phase 3 SELECT-BEYOND clinical trial evaluating upadacitinib (ABT-494), an investigational oral JAK1-selective inhibitor, in patients with moderate to severe rheumatoid arthritis (RA) who did not adequately respond or were intolerant to treatment with biologic DMARDs (bDMARDs).1 Results showed that after 12 weeks of treatment, both once-daily doses of upadacitinib (15 mg and 30 mg) met the study's primary endpoints of ACR20* and low disease activity (LDA)**.1 All ranked secondary endpoints were also achieved with both doses.1 Upadacitinib is not... More

Abbvie (ABBV): IPR Victory Translates Into A 36% PT Increase - Cowen

September 11, 2017 6:16 AM EDT

Cowen analyst, Steve Scala, reiterated his Outperform rating on shares of Abbvie (NYSE: ABBV) and raised his price target to $95 from $70 noting that last week's IPR victory targeting a Humira formulation patent is important leading the analyst to give ABBV the... More